Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders
Modern neuropsychopharmacology commenced in the 1950s with the serendipitous discovery of first-generation antipsychotics and antidepressants which were therapeutically effective yet had marked adverse effects. Today, a broader palette of safer and better-tolerated agents is available for helping pe...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
May 2015
|
| In: |
European neuropsychopharmacology
Year: 2015, Jahrgang: 25, Heft: 5, Pages: 599-656 |
| ISSN: | 1873-7862 |
| DOI: | 10.1016/j.euroneuro.2015.01.016 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/j.euroneuro.2015.01.016 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0924977X15000176 
|
| Verfasserangaben: | Mark J. Millan, Guy M. Goodwin, Andreas Meyer-Lindenberg, Sven Ove Ögren |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1566166462 | ||
| 003 | DE-627 | ||
| 005 | 20230426064422.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171207s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.euroneuro.2015.01.016 |2 doi | |
| 035 | |a (DE-627)1566166462 | ||
| 035 | |a (DE-576)496166468 | ||
| 035 | |a (DE-599)BSZ496166468 | ||
| 035 | |a (OCoLC)1340982973 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Millan, Mark J. |d 1956- |e VerfasserIn |0 (DE-588)1148034951 |0 (DE-627)1007516488 |0 (DE-576)49616631X |4 aut | |
| 245 | 1 | 0 | |a Learning from the past and looking to the future |b emerging perspectives for improving the treatment of psychiatric disorders |c Mark J. Millan, Guy M. Goodwin, Andreas Meyer-Lindenberg, Sven Ove Ögren |
| 264 | 1 | |c May 2015 | |
| 300 | |a 58 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 07.12.2017 | ||
| 520 | |a Modern neuropsychopharmacology commenced in the 1950s with the serendipitous discovery of first-generation antipsychotics and antidepressants which were therapeutically effective yet had marked adverse effects. Today, a broader palette of safer and better-tolerated agents is available for helping people that suffer from schizophrenia, depression and other psychiatric disorders, while complementary approaches like psychotherapy also have important roles to play in their treatment, both alone and in association with medication. Nonetheless, despite considerable efforts, current management is still only partially effective, and highly-prevalent psychiatric disorders of the brain continue to represent a huge personal and socio-economic burden. The lack of success in discovering more effective pharmacotherapy has contributed, together with many other factors, to a relative disengagement by pharmaceutical firms from neuropsychiatry. Nonetheless, interest remains high, and partnerships are proliferating with academic centres which are increasingly integrating drug discovery and translational research into their traditional activities. This is, then, a time of transition and an opportune moment to thoroughly survey the field. Accordingly, the present paper, first, chronicles the discovery and development of psychotropic agents, focusing in particular on their mechanisms of action and therapeutic utility, and how problems faced were eventually overcome. Second, it discusses the lessons learned from past successes and failures, and how they are being applied to promote future progress. Third, it comprehensively surveys emerging strategies that are (1), improving our understanding of the diagnosis and classification of psychiatric disorders; (2), deepening knowledge of their underlying risk factors and pathophysiological substrates; (3), refining cellular and animal models for discovery and validation of novel therapeutic agents; (4), improving the design and outcome of clinical trials; (5), moving towards reliable biomarkers of patient subpopulations and medication efficacy and (6), promoting collaborative approaches to innovation by uniting key partners from the regulators, industry and academia to patients. Notwithstanding the challenges ahead, the many changes and ideas articulated herein provide new hope and something of a framework for progress towards the improved prevention and relief of psychiatric and other CNS disorders, an urgent mission for our Century. | ||
| 650 | 4 | |a Depression | |
| 650 | 4 | |a ADHD | |
| 650 | 4 | |a Anxiety | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Bipolar | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a Discovery | |
| 650 | 4 | |a DSM | |
| 650 | 4 | |a Epigenetics | |
| 650 | 4 | |a Genetics | |
| 650 | 4 | |a Genomics | |
| 650 | 4 | |a iPSC | |
| 650 | 4 | |a OCD | |
| 650 | 4 | |a Personalised | |
| 650 | 4 | |a Prevention | |
| 650 | 4 | |a Schizophrenia | |
| 650 | 4 | |a Translational | |
| 700 | 1 | |a Meyer-Lindenberg, Andreas |d 1965- |e VerfasserIn |0 (DE-588)1029137390 |0 (DE-627)732483069 |0 (DE-576)376589876 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European neuropsychopharmacology |d Amsterdam : Elsevier, 1990 |g 25(2015), 5, Seite 599-656 |h Online-Ressource |w (DE-627)320594025 |w (DE-600)2019305-1 |w (DE-576)266224334 |x 1873-7862 |7 nnas |a Learning from the past and looking to the future emerging perspectives for improving the treatment of psychiatric disorders |
| 773 | 1 | 8 | |g volume:25 |g year:2015 |g number:5 |g pages:599-656 |g extent:58 |a Learning from the past and looking to the future emerging perspectives for improving the treatment of psychiatric disorders |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.euroneuro.2015.01.016 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0924977X15000176 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171207 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 1029137390 |a Meyer-Lindenberg, Andreas |m 1029137390:Meyer-Lindenberg, Andreas |d 60000 |e 60000PM1029137390 |k 0/60000/ |p 3 | ||
| 999 | |a KXP-PPN1566166462 |e 2989530770 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Mark J.","role":"aut","family":"Millan","display":"Millan, Mark J."},{"display":"Meyer-Lindenberg, Andreas","family":"Meyer-Lindenberg","given":"Andreas","role":"aut"}],"relHost":[{"pubHistory":["1.1990/91 -"],"titleAlt":[{"title":"ENP"}],"part":{"year":"2015","volume":"25","pages":"599-656","text":"25(2015), 5, Seite 599-656","extent":"58","issue":"5"},"id":{"zdb":["2019305-1"],"eki":["320594025"],"issn":["1873-7862"]},"origin":[{"publisherPlace":"Amsterdam","dateIssuedKey":"1990","dateIssuedDisp":"1990-","publisher":"Elsevier"}],"title":[{"title":"European neuropsychopharmacology","title_sort":"European neuropsychopharmacology","subtitle":"ENP ; the journal of the European College of Neuropsychopharmacology"}],"note":["Gesehen am 31.01.20"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"recId":"320594025","physDesc":[{"extent":"Online-Ressource"}],"disp":"Learning from the past and looking to the future emerging perspectives for improving the treatment of psychiatric disordersEuropean neuropsychopharmacology"}],"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"May 2015"}],"note":["Gesehen am 07.12.2017"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"title":[{"subtitle":"emerging perspectives for improving the treatment of psychiatric disorders","title":"Learning from the past and looking to the future","title_sort":"Learning from the past and looking to the future"}],"physDesc":[{"extent":"58 S."}],"recId":"1566166462","name":{"displayForm":["Mark J. Millan, Guy M. Goodwin, Andreas Meyer-Lindenberg, Sven Ove Ögren"]},"id":{"doi":["10.1016/j.euroneuro.2015.01.016"],"eki":["1566166462"]}} | ||
| SRT | |a MILLANMARKLEARNINGFR2015 | ||